Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapeutic approach, particularly for oncohematological patients who are refractory to conventional treatments. As clinical trials expand the applications of CAR T-cell therapy beyond hematologic malignancies, a cr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1578157/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148593642504192 |
|---|---|
| author | Jia-Hui Liu Jia-Hui Liu Jia-Hui Liu Kun-Yao Liu Xiang Zhao Xin Zhou Xin Zhou Xin Zhou Yichuan Jiang Yichuan Jiang |
| author_facet | Jia-Hui Liu Jia-Hui Liu Jia-Hui Liu Kun-Yao Liu Xiang Zhao Xin Zhou Xin Zhou Xin Zhou Yichuan Jiang Yichuan Jiang |
| author_sort | Jia-Hui Liu |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapeutic approach, particularly for oncohematological patients who are refractory to conventional treatments. As clinical trials expand the applications of CAR T-cell therapy beyond hematologic malignancies, a critical understanding of its associated toxicities, particularly cardiovascular complications, becomes imperative. This review synthesizes current literature on the interplay between cytokine release syndrome (CRS) and cardiotoxicity related to CAR T-cell therapy, emphasizing the potential severity of these adverse events. While significant progress has been made in managing CRS, the cardiac manifestations—ranging from mild events to life-threatening complications—remain underreported in pivotal studies. We explore the incidence and nature of cardiotoxicity in real-world and clinical trial settings, identify risk factors contributing to cardiovascular events, and propose guidelines for pre-therapy evaluations, post-infusion monitoring, and management strategies. By highlighting the urgent need for heightened awareness and proactive care, this review aims to enhance patient safety and optimize outcomes in the evolving landscape of CAR T-cell therapy. |
| format | Article |
| id | doaj-art-a94bd388bd744e29862d274a2f1250b4 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-a94bd388bd744e29862d274a2f1250b42025-08-20T02:27:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15781571578157Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapyJia-Hui Liu0Jia-Hui Liu1Jia-Hui Liu2Kun-Yao Liu3Xiang Zhao4Xin Zhou5Xin Zhou6Xin Zhou7Yichuan Jiang8Yichuan Jiang9Cancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, ChinaInternational Center of Future Science, Jilin University, Changchun, ChinaCancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, ChinaCancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, ChinaCancer Center, The First Hospital of Jilin University, Changchun, ChinaCancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, ChinaInternational Center of Future Science, Jilin University, Changchun, ChinaDepartment of Pharmacy, China-Japan Union Hospital of Jilin University, Changchun, ChinaDepartment of Clinical Pharmacy, The First Hospital of Jilin University, Changchun, ChinaChimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapeutic approach, particularly for oncohematological patients who are refractory to conventional treatments. As clinical trials expand the applications of CAR T-cell therapy beyond hematologic malignancies, a critical understanding of its associated toxicities, particularly cardiovascular complications, becomes imperative. This review synthesizes current literature on the interplay between cytokine release syndrome (CRS) and cardiotoxicity related to CAR T-cell therapy, emphasizing the potential severity of these adverse events. While significant progress has been made in managing CRS, the cardiac manifestations—ranging from mild events to life-threatening complications—remain underreported in pivotal studies. We explore the incidence and nature of cardiotoxicity in real-world and clinical trial settings, identify risk factors contributing to cardiovascular events, and propose guidelines for pre-therapy evaluations, post-infusion monitoring, and management strategies. By highlighting the urgent need for heightened awareness and proactive care, this review aims to enhance patient safety and optimize outcomes in the evolving landscape of CAR T-cell therapy.https://www.frontiersin.org/articles/10.3389/fphar.2025.1578157/fullCAR T cellcardio-oncologycytokine release syndromecardiotoxicitychimeric antigen receptor |
| spellingShingle | Jia-Hui Liu Jia-Hui Liu Jia-Hui Liu Kun-Yao Liu Xiang Zhao Xin Zhou Xin Zhou Xin Zhou Yichuan Jiang Yichuan Jiang Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy Frontiers in Pharmacology CAR T cell cardio-oncology cytokine release syndrome cardiotoxicity chimeric antigen receptor |
| title | Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy |
| title_full | Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy |
| title_fullStr | Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy |
| title_full_unstemmed | Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy |
| title_short | Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy |
| title_sort | cardiovascular toxicities associated with chimeric antigen receptor t cell therapy |
| topic | CAR T cell cardio-oncology cytokine release syndrome cardiotoxicity chimeric antigen receptor |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1578157/full |
| work_keys_str_mv | AT jiahuiliu cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT jiahuiliu cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT jiahuiliu cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT kunyaoliu cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT xiangzhao cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT xinzhou cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT xinzhou cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT xinzhou cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT yichuanjiang cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy AT yichuanjiang cardiovasculartoxicitiesassociatedwithchimericantigenreceptortcelltherapy |